Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Holowiecki J, et al. Among authors: grosicki s. Leukemia. 2004 May;18(5):989-97. doi: 10.1038/sj.leu.2403336. Leukemia. 2004. PMID: 14999298 Clinical Trial.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. Brown JR, et al. Among authors: grosicki s. N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13. N Engl J Med. 2023. PMID: 36511784 Clinical Trial.
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosińska J, Hellmann A, Czyz J, Hołowiecki J, Kopera M, Grosicki S, Komarnicki M, Rumianowski L, Kuliczkowski K, Wróbel T, Dwilewicz-Trojaczek J, Robak T, Warzocha K, Załuski J, Wójcik E, Dmoszyńska A, Walter-Croneck A; Polish Lymphoma Research Group. Walewski J, et al. Among authors: grosicki s. Med Oncol. 2001;18(2):141-8. doi: 10.1385/mo:18:2:141. Med Oncol. 2001. PMID: 11778760 Clinical Trial.
G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study.
Hołowiecki J, Giebel S, Krzemień S, Krawczyk-Kuliś M, Jagoda K, Kopera M, Hołowiecka B, Grosicki S, Hellmann A, Dmoszyńska A, Paluszewska M, Robak T, Konopka L, Maj S, Wojnar J, Wojciechowska M, Skotnicki A, Baran W, Cioch M. Hołowiecki J, et al. Among authors: grosicki s. Leuk Lymphoma. 2002 Feb;43(2):315-25. doi: 10.1080/10428190290006099. Leuk Lymphoma. 2002. PMID: 11999563 Clinical Trial.
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Among authors: grosicki s. Eur J Haematol. 2003 Sep;71(3):155-62. doi: 10.1034/j.1600-0609.2003.00122.x. Eur J Haematol. 2003. PMID: 12930315 Clinical Trial.
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Among authors: grosicki s. Ann Hematol. 2005 Sep;84(9):557-64. doi: 10.1007/s00277-005-1046-0. Epub 2005 Apr 27. Ann Hematol. 2005. PMID: 15856358 Clinical Trial.
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.
Holowiecki J, Grosicki S, Sadus-Wojciechowska M, Kachel L, Hellmann A, Mital A, Skotnicki AB, Piatkowska-Jakubas B, Jedrzejczak WW, Paluszewska M, Wach M, Marianska B, Wrzesien-Kus A, Krawczyk-Kulis M, Wojnar J. Holowiecki J, et al. Among authors: grosicki s. Transplant Proc. 2005 Dec;37(10):4482-7. doi: 10.1016/j.transproceed.2005.10.100. Transplant Proc. 2005. PMID: 16387150
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B. Hołowiecki J, et al. Among authors: grosicki s. Ann Hematol. 2008 May;87(5):361-7. doi: 10.1007/s00277-007-0421-4. Epub 2007 Dec 12. Ann Hematol. 2008. PMID: 18074133 Clinical Trial.
144 results